CLL1 polymeric nanoparticles loaded with PI3K/BRD4 dual inhibitor MDP5 and azacitidine as a novel treatment for TP53 mutated acute myeloid leukemia.

Abstract excerpt

Acute myeloid leukemia (AML) in older adults, particularly with mutation in the tumor suppressor gene TP53, has high rates of resistance to standard chemotherapy regimens, often resulting in patients death within months of diagnosis. To address this unmet need, we investigated the therapeutic potential of targeted nanoparticles (NPs) loaded with MDP5 (our novel BRD4/PI3K dual inhibitor) and azacitidine (AZA), a...

Topics

Join the communities discussing this publication.

• Azacitidine
• Leukemia, Myeloid, Acute
• Mice, SCID
• Nanoparticles
• Phosphoinositide-3 Kinase Inhibitors